Article
Maxim Pharmaceuticals has announced that advanced metastatic melanoma patients treated with a combination of Ceplene and Interleukin-2 (IL-2) showed improved survival rates in a phase 3 trial, according to a Business Wire report.
Day 1 Recap: SBS 2025
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Beyond Topicals: Surgical Solutions for Vitiligo
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Balancing Adolescent Acne Treatment and Well-being
The Future of Pediatric Care at MOPD